- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108757
Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients (PRECAUTION)
October 17, 2017 updated by: The Cleveland Clinic
Prevention of Catheter-Associated Urinary Tract Infections in Patients Undergoing Incontinence and Reconstructive Pelvic Surgery: A Randomized Controlled Trial
The study will assess the risk of catheter associated urinary tract infection in women undergoing incontinence or reconstructive pelvic surgery.
Women will be given an antibiotic or placebo at the time of catheter removal.
The investigators hypothesize that prophylactic antibiotics will reduce the rate of infection.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Requires catheterization >24h hours following incontinence or pelvic reconstructive surgery
Exclusion Criteria:
- Receipt of antibiotics for either prophylaxis or treatment of a known infection during the postoperative hospitalization
- Allergy to sulfonamides or trimethoprim
- Non-English speaking
- Pregnancy
- Breast feeding
- Severe renal impairment (creatinine clearance <30)
- Patients taking dofetilide, methenamine, procaine, warfarin, procainamide, methotrexate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Corn starch capsules
|
Experimental: Drug
|
Bactrim DS BID for 3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Urinary Tract Infection
Time Frame: 7 days following catheter removal
|
Urinary tract infection diagnosis was obtained after confirmation with urine culture microbiology report.
Infection was defined as >100,000 colony forming units/mL
|
7 days following catheter removal
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew D Barber, MD MHS, The Cleveland Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
April 21, 2010
First Submitted That Met QC Criteria
April 21, 2010
First Posted (Estimate)
April 22, 2010
Study Record Updates
Last Update Posted (Actual)
October 18, 2017
Last Update Submitted That Met QC Criteria
October 17, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Infections
- Communicable Diseases
- Urinary Tract Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anti-Infective Agents, Urinary
- Renal Agents
- Trimethoprim, Sulfamethoxazole Drug Combination
Other Study ID Numbers
- 10-125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Catheter-Associated Urinary Tract Infection
-
Mayo ClinicCompletedUrinary Tract Infection | Infection Associated With CatheterUnited States
-
Joshua SwanThe Methodist Hospital Research Institute; Texas Southern UniversityCompletedCross Infection | Surgical Wound Infection | Pneumonia, Ventilator-associated | Catheter-related Infections | Infection Due to Indwelling Urinary CatheterUnited States
-
Medline IndustriesCompletedCatheter-Associated Urinary Tract InfectionUnited States
-
Imperial College LondonCompletedSmart Catheter: A Novel Biosensor for Early Detection of Catheter Associated Urinary Tract InfectionCatheter-Associated Urinary Tract InfectionUnited Kingdom
-
American University of Beirut Medical CenterWithdrawnCatheter-Associated Urinary Tract Infection, Ascorbic AcidLebanon
-
Wake Forest University Health SciencesCompletedCatheter-Associated Urinary Tract InfectionUnited States
-
Hospital do CoracaoHospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital Sirio-Libanes and other collaboratorsActive, not recruitingVentilator Associated Pneumonia | Health Care Associated Infection | Catheter-Associated Urinary Tract Infection | Central Line-associated Bloodstream Infection (CLABSI)Brazil
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompletedCatheter-associated Urinary Tract InfectionChina
-
Khon Kaen UniversityCompletedCritically Ill Patients | Catheter Associated Urinary Tract InfectionThailand
-
Fudan UniversityShanghai Zhongshan Hospital; Huashan Hospital; Children's Hospital of Fudan University and other collaboratorsRecruitingQuality Improvement | Central Venous Catheter Associated Bloodstream Infection | CLABSI - Central Line Associated Bloodstream Infection | Central Venous Catheter Related Bloodstream Infection | Central Line Infection | CRBSI - Catheter Related Bloodstream Infection | Evidence-based Nursing PracticeChina
Clinical Trials on Bactrim
-
University of WashingtonCompleted
-
William Beaumont HospitalsTerminated
-
59th Medical WingEmergency Medicine FoundationCompleted
-
Johns Hopkins UniversityWithdrawnBacteriuria | Antibiotic Resistant Infection | Microtia | UTI | Antibiotics Causing Adverse Effects in Therapeutic Use
-
59th Medical WingEmergency Medicine Foundation; U.S. Air Force Office of the Surgeon GeneralCompletedAbscess | Methicillin-Resistant Staphylococcus Aureus InfectionUnited States
-
Tor Erik SandUnknownUreteric Stent After Stone SurgeryNorway
-
University of WashingtonKenya Medical Research InstituteCompletedHIV Infections | Acquired Immunodeficiency Syndrome | Immune System Diseases | Pneumonia | Disease Progression | Diarrhea | Parasitic Diseases | Malaria | Infectious Disorder of Immune SystemKenya
-
Emory UniversityWithdrawnComplications; Breast Prosthesis, Infection or Inflammation
-
R. Stephen Rankin, M.D.UnknownCommunity-acquired Methicillin-resistant Staphylococcus Aureus InfectionUnited States
-
University of OxfordKenya Medical Research InstituteCompletedNutrition Disorders | Life-threatening InfectionKenya